
Philip Vlummens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1569172/publications.pdf Version: 2024-02-01



DHILLD VILLMMENS

#	Article	IF	CITATIONS
1	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. European Journal of Haematology, 2022, 108, 369-378.	1.1	5
2	Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis. Journal of Experimental and Clinical Cancer Research, 2022, 41, 45.	3.5	13
3	System Xcâ^² inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. Cancer Letters, 2022, 535, 215649.	3.2	11
4	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma Journal of Clinical Oncology, 2022, 40, TPS8070-TPS8070.	0.8	1
5	Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 46-54.e4.	0.2	11
6	A mini-review on aplastic anemia, illustrated by a case report on bone marrow hot pockets mimicking sclerotic bone metastases. Acta Clinica Belgica, 2021, , 1-6.	0.5	0
7	G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death. Blood Advances, 2021, 5, 2325-2338.	2.5	19
8	Subgroup analysis of ICARIAâ€MM study in relapsed/refractory multiple myeloma patients with highâ€risk cytogenetics. British Journal of Haematology, 2021, 194, 120-131.	1.2	27
9	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC Cancer, 2021, 21, 993.	1.1	8
10	Pyrroline-5-Carboxylate Reductase 1: A Novel Target for Sensitizing Myeloma to Cytotoxic Agents By Inhibition of PRAS40-Mediated Protein Synthesis. Blood, 2021, 138, 1574-1574.	0.6	0
11	CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. Oncolmmunology, 2021, 10, 2000699.	2.1	9
12	Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	13.9	460
13	The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2019, 10, 740.	1.1	5
14	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer, 2019, 120, 1137-1146.	2.9	12
15	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica, 2019, 104, 2274-2282.	1.7	27
16	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal, 2019, 9, 87.	2.8	7
17	The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers, 2019, 11, 1823.	1.7	36
18	Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters, 2019, 442, 233-241.	3.2	49

#	Article	IF	CITATIONS
19	Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature. Acta Clinica Belgica, 2019, 74, 359-363.	0.5	2
20	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. Blood, 2019, 134, 3140-3140.	0.6	13
21	The genetic landscape of 5T models for multiple myeloma. Scientific Reports, 2018, 8, 15030.	1.6	15
22	Cutaneous mucormycosis as result of insulin administration in an AML patient: Case report and review of the literature. Acta Clinica Belgica, 2017, 72, 352-356.	0.5	4